MFN and IRP analysis for innovative oncology therapies ​

• There was a requirement for an analysis of the application of MFN on the global revenue potential for a selection of innovative oncology therapies ​
• This was needed to quantify the commercial risks associated with ex-US launch for new oncology assets, and potential variation according to whether MFN referencing is based on list or volume-weighted average net prices across global markets (adjusted for purchasing power parity) ​

‍

• Complete a comprehensive analysis of the proposed MFN policy framework and practical implications for global pricing strategy development and implementation for innovative cancer therapies​
• Analysis of the potential variation in US net pricing impact depending on referencing based on list or volume-weighted average net prices across global reference markets​
• Scenario analysis depending on product availability across international reference markets and the scale of list/net price differential across reference markets  ​

‍

• We supported with the development of potential scenarios regarding the global pricing corridor for the innovative oncology therapies (including expectations for list/net pricing differentials across MFN reference markets in North America, Europe and APAC)​
• Detailed analysis was completed using the SyMAP framework to inform the implications for the US price benchmark/commercial opportunity, potential  price/revenue variation according to agreed scenarios, and implications for the optimal commercial strategy​

• A clear analysis was provided regarding the commercial implications of the MFN policy framework, variation in the US pricing/commercial impact depending on agreed scenarios (including MFN referencing based on list or volume-weighted average net prices across global reference markets, adjusted for purchasing power parity) and strategic implications for the ex-US launch strategy/sequencing requirements for innovative oncology therapies  ​

‍